UAE Ministry Of Health Approves Biomerica’s Fortel® Ulcer Test For H. Pylori Detection, Marking Key Milestone

Biomerica, Inc., a global provider of advanced diagnostic solutions, has announced that its Fortel® Ulcer Test has received approval for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory approval allows Biomerica to introduce its rapid point-of-care test for Helicobacter pylori (H. pylori) infection across the UAE, a region where gastrointestinal diseases are becoming an increasing public health concern. The Fortel® Ulcer Test is a simple, fast, and user-friendly diagnostic tool designed to detect antibodies to H. pylori, a bacterium responsible for causing conditions such as peptic ulcer disease, dyspepsia, and gastric cancer. The test provides accurate results in just 10 minutes, making it an efficient option for quick diagnosis and treatment.

H. pylori affects about 35% of the population in the United States and 45% in the five largest European countries. In the UAE, studies suggest that infection rates exceed 50%, particularly among certain age groups and ethnic communities. Alarmingly, 15-20% of infected individuals may develop complications, including peptic ulcers, chronic digestive symptoms, and even gastric cancer. Gastric cancer is the third most common cause of cancer-related deaths worldwide, with approximately 80% of these cases linked to H. pylori infection. Recognizing its significant health risks, the World Health Organization (WHO) has designated H. pylori as one of the top 16 antibiotic-resistant bacteria posing the greatest threat to human health, classifying it as a Class 1 carcinogen.

Zack Irani, CEO of Biomerica, said in a statement, “The Fortel® Ulcer Test empowers healthcare providers to rapidly detect H. pylori infection and take timely action to prevent serious gastrointestinal diseases, including cancer. We’re proud to support the UAE’s health system with this important tool for earlier detection and better outcomes.”

This approval represents an important step in Biomerica’s expansion into the Middle East, following the successful launch of other diagnostic products such as the EZ Detect™ Colon Disease Test in the region. The company is working with local distributors and healthcare providers to ensure that the Fortel® Ulcer Test is available throughout the UAE. Biomerica remains committed to delivering affordable, innovative diagnostic solutions aimed at improving patient outcomes through early disease detection. The Fortel® Ulcer Test is part of the company's broader mission to enhance global health by providing fast, accessible diagnostics to help address H. pylori-related illnesses.